Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aurelius Health Group vs Mixx Health & Wellness

Aurelius Health Group
Graded #311

Lower grade

vs+2
Mixx Health & Wellness
Graded #266

Higher grade

The verdict

Mixx Health & Wellness takes it — 62.8/100 to 60.8/100, but only just.

Mixx Health & Wellness grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mixx Health & Wellness is a telehealth weight-loss platform offering compounded semaglutide and tirzepatide from $120/month with $0 consultations and follow-ups. Aurelius Health Group is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMixx Health & Wellness +25
54
79
Dose & formulationAurelius Health Group +12
52
40
Clinical oversightAurelius Health Group +12
76
64
Labs & monitoringEven
63
63
FulfillmentMixx Health & Wellness +9
61
70
Contract termsAurelius Health Group +6
61
55
Aurelius Health Group · left barMixx Health & Wellness · right bar

The numbers

MetricAurelius Health GroupMixx Health & Wellness
WeighScore60.8/10062.8/100
GradeCC
Scorecard rank#311#266
SemaglutideNot disclosedNot disclosed
Tirzepatide$199/mo (microdose tier, compounded)Not disclosed
CoverageCoverage not published44 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Aurelius Health Group

Graded #311 · C

Strengths

  • Pricing fully published and bundled: $89 first month, then $199/mo all-in — more transparent than most compounded brands
  • LegitScript Certified
  • Care-inclusive model: consults, monthly monitoring, and secure messaging rather than Rx-only
  • Unusually candid about the limited evidence base for microdosing

Where it loses points

  • The advertised $89 is a first-month new-patient rate; every month after it is $199
  • This is a 1 mg microdose programme and nothing else — no labelled therapeutic dose is sold, so it is not an alternative to a full-dose prescription
  • No state count is published, only 'most US states', confirmed at intake
  • The site's own comparison table calls 2.4 mg/week the tirzepatide 'standard full dose'; 2.4 mg is the semaglutide maintenance dose, and tirzepatide is labelled 2.5-15 mg/week
  • Compounded tirzepatide is not an FDA-approved finished product
Mixx Health & Wellness

Graded #266 · C

Strengths

  • 44 jurisdictions enumerated in the public FAQ — confirm eligibility before intake
  • Operating LLC disclosed: Mixx Health and Wellness LLC (Wyoming law)
  • Named pharmacy partner: Promise Pharmacy, Palm Harbor FL, (727) 772-0500
  • Named founder: Dr. James David Lawrence III, MD, with a public origin story
  • $0 consultation fee — free intake and follow-ups

Where it loses points

  • Both medications are compounded semaglutide and tirzepatide — not FDA-approved brand drugs
  • Dose-tier pricing not available — /pricing and /products pages returned 404
  • No LegitScript, PCAB, or BBB trust badges visible
  • Wyoming governing-law clause — disputes adjudicated under Wyoming law regardless of your state
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard